Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report
- PMID: 38817215
- PMCID: PMC11135446
- DOI: 10.12998/wjcc.v12.i15.2621
Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: A case report
Abstract
Background: Acute upper gastrointestinal bleeding is a common medical emergency that has a 10% hospital mortality rate. According to the etiology, this disease can be divided into acute varicose veins and nonvaricose veins. Bleeding from esophageal varices is a life-threatening complication of portal hypertension. Portal hypertension is a clinical syndrome defined as a portal venous pressure that exceeds 10 mmHg. Cirrhosis is the most common cause of portal hypertension, and thrombosis of the portal system not associated with liver cirrhosis is the second most common cause of portal hypertension in the Western world. Primary myeloproliferative disorders are the main cause of portal venous thrombosis, and somatic mutations in the Janus kinase 2 gene (JAK2 V617F) can be found in approximately 90% of polycythemia vera, 50% of essential thrombocyrosis and 50% of primary myelofibrosis.
Case summary: We present a rare case of primary myelofibrosis with gastrointestinal bleeding as the primary manifestation that presented as portal-superior-splenic mesenteric vein thrombosis. Peripheral blood tests revealed the presence of the JAK2 V617F mutation. Bone marrow biopsy ultimately confirmed the diagnosis of myelofibrosis (MF-2 grade).
Conclusion: In patients with acute esophageal variceal bleeding due to portal hypertension and vein thrombosis without cirrhosis, the possibility of myeloproliferative neoplasms should be considered, and the JAK2 mutation test should be performed.
Keywords: Acute esophageal variceal bleeding; Case report; JAK2 V617F mutation; Myelofibrosis; Portal hypertension.
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: We declare that we have no financial and personal relationships with other people ororganizations that can inappropriately influence our work, there is no professional or other personal interest of anynature or kind in any product, service and/or company that could be construed as influencing the position presentedin, or the review of, the manuscript entitled.
Figures

Similar articles
-
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.Int J Surg Case Rep. 2016;28:93-96. doi: 10.1016/j.ijscr.2016.08.013. Epub 2016 Aug 13. Int J Surg Case Rep. 2016. PMID: 27693837 Free PMC article.
-
Primary Myelofibrosis in the Prefibrotic Stage Presenting as Portal, Splenic, and Superior Mesenteric Vein Thrombosis: A Case Report and Review of the Literature.GE Port J Gastroenterol. 2021 May 4;29(2):125-131. doi: 10.1159/000514658. eCollection 2022 Mar. GE Port J Gastroenterol. 2021. PMID: 35497670 Free PMC article.
-
Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.Cochrane Database Syst Rev. 2021 Jan 26;1(1):CD011561. doi: 10.1002/14651858.CD011561.pub2. Cochrane Database Syst Rev. 2021. PMID: 33522602 Free PMC article.
-
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Orv Hetil. 2011. PMID: 22011365 Hungarian.
-
Sclerotherapy versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis.Cochrane Database Syst Rev. 2020 Mar 5;3(3):CD011573. doi: 10.1002/14651858.CD011573.pub2. Cochrane Database Syst Rev. 2020. PMID: 32133620 Free PMC article.
References
-
- Acute upper gastrointestinal bleeding in over 16s: management. London: National Institute for Health and Care Excellence (NICE); 2016 Aug- - PubMed
-
- Valla DC, Condat B, Lebrec D. Spectrum of portal vein thrombosis in the West. J Gastroenterol Hepatol. 2002;17 Suppl 3:S224–S227. - PubMed
-
- Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score. Blood Cancer J. 2022;12:156. - PMC - PubMed
-
- Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–4928. - PubMed
-
- Spivak JL. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med. 2010;152:300–306. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous